Menu
Enrolling by invitation NCT06596148

Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression

No phase Interventional Immunosuppresion

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Access to Shingrix dashboard.
Who it may be relevant to
Registry conditions: Immunosuppresion. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

VA Quality Improvement Research and Training Initiative

Overview

The goal of this wait-list control trial is to learn if having access to a new dashboard displaying information about immunosuppressed Veterans missing vaccinations for Shingrix can improve Shingrix vaccination rates at VA facilities. The main question\[s\] it aims to answer is: Will vaccination rates improve more rapidly for facilities with access to the dashboard compare to facilities without access? VA facility personnel will be granted access to the dashboard and outcomes (vaccination rates) will be measured using electronic health record data.

Detailed description

Assignment of the intervention will occur at the facility level. Outcomes (vaccination) will be assessed for patients cared for at each facility.

Interventions

  • Other Access to Shingrix dashboard
    The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic h

Primary outcome measures

  • Percentage of patients with at least 1 Shingrix vaccine documented, by facility [Time frame: From enrollment until end of follow up at 18 months.]
Secondary outcome measures (1)
  • Percentage of patients with at least 2 Shingrix vaccinations documented, by facility [Time frame: From enrollment until end of follow up at 18 months.]

Eligibility criteria

Inclusion criteria

  • In order to be included in the study, clinicians need to work at a VHA facility and have access to the electronic health record.

Exclusion criteria

  • None.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 1 center
  • San Francisco VA — San Francisco

Identifiers

NCT: NCT06596148 · 15-18358- SHINGRIX · I50HX003266

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗